Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 5/20 | 0.47 |
| ▸ | FAAH | O00519 | 2/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | POLA1 | P09884 | 1/20 | 0.44 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | DGKA | P23743 | 1/20 | 0.44 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | ICMT | O60725 | 1/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.39 |
| ▸ | THRA | P10827 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15880164 | 1.00 | KDM5A (0.47) | KDM5AFAAHDNM1POLBPOLA1 | |
| SCHEMBL19032444 | 1.00 | KDM5A (0.47) | KDM5AFAAHDNM1POLBPOLA1 | |
| SCHEMBL8335342 | 1.00 | KDM5A (0.47) | KDM5AFAAHDNM1POLBPOLA1 | |
| SCHEMBL16922399 | 1.00 | KDM5A (0.47) | KDM5AFAAHDNM1POLBPOLA1 | |
| Hydrochloric Acid SCHEMBL27082309 | 0.98 | KDM5A (0.46) | KDM5AFAAHDNM1POLBPOLA1 | |
| SCHEMBL19032377 | 0.96 | KDM5A (0.45) | KDM5AFAAHDNM1POLBPOLA1 | |
| SCHEMBL19032563 | 0.96 | KDM5A (0.45) | KDM5AFAAHDNM1POLBPOLA1 | |
| SCHEMBL18954314 | 0.96 | KDM5A (0.45) | KDM5AFAAHDNM1POLBPOLA1 | |
| SCHEMBL19032471 | 0.96 | KDM5A (0.45) | KDM5AFAAHDNM1POLBPOLA1 | |
| SCHEMBL8337930 | 0.96 | KDM5A (0.47) | KDM5AFAAHDNM1POLBPOLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3638678-B1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX INC (US) | 2025-12-03 | — | — | EP | disclosed |
| EP-4036079-B1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX INC (US) | 2025-11-19 | — | — | EP | disclosed |
| US-12396961-B2 | Compounds and compositions for intracellular delivery of agents | MODERNATX, INC. (US) | 2025-08-26 | — | — | US | disclosed |
| EP-3394030-B2 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX INC (US) | 2025-02-12 | — | — | EP | disclosed |
| US-12077501-B2 | Compounds and compositions for intracellular delivery of agents | MODERNATX, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| EP-4036079-A2 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | ModernaTX, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| EP-3394030-B1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX INC (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3394030-B1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX INC (US) | 2021-12-22 | — | — | EP | disclosed |
| US-20210198200-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2021-07-01 | — | — | US | disclosed |
| US-20210198200-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2021-07-01 | — | — | US | disclosed |
| US-10799463-B2 | Compounds and compositions for intracellular delivery of agents | MODERNATX, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| EP-3638678-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | Modernatx, Inc. (US) | 2020-04-22 | — | — | EP | disclosed |
| US-10195156-B2 | Compounds and compositions for intracellular delivery of agents | MODERNATX, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-10195156-B2 | Compounds and compositions for intracellular delivery of agents | MODERNATX, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20180369419-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | Moderna TX, Inc. (US) | 2018-12-27 | — | — | US | disclosed |
| WO-2018232120-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2018-12-20 | — | — | WO | disclosed |
| US-20180333366-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2018-11-22 | — | — | US | disclosed |
| EP-3394030-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | Modernatx, Inc. (US) | 2018-10-31 | — | — | EP | disclosed |
| WO-2017112865-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
| WO-2017112865-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10195156-B2 | Compounds and compositions for intracellular delivery of agents | LNPK, PLTP, PHOSPHO1 | KDM5A 4758/4885FAAH 3097/4885DNM1 1160/4885 |
| US-20210198200-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | LNPK, PLTP, PHOSPHO1 | KDM5A 4758/4885FAAH 3097/4885DNM1 1160/4885 |
| US-12396961-B2 | Compounds and compositions for intracellular delivery of agents | LNPK, PLTP, PHOSPHO1 | KDM5A 4758/4885FAAH 3097/4885DNM1 1160/4885 |
| US-20180369419-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | LNPK, PLTP, PHOSPHO1 | KDM5A 4758/4885FAAH 3097/4885DNM1 1160/4885 |
| US-20180333366-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | LNPK, PLTP, PHOSPHO1 | KDM5A 4758/4885FAAH 3097/4885DNM1 1160/4885 |
| US-12077501-B2 | Compounds and compositions for intracellular delivery of agents | LNPK, PLTP, PHOSPHO1 | KDM5A 4758/4885FAAH 3097/4885DNM1 1160/4885 |
| US-10799463-B2 | Compounds and compositions for intracellular delivery of agents | LNPK, PLTP, PHOSPHO1 | KDM5A 4758/4885FAAH 3097/4885DNM1 1160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.